http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2613071-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d7b69a1a9074f89644a48ecf937fc41 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2015-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ada2176111e7a5086ed1d738b6d93ec4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94e5ed2a0a1f8b9743b6d52fef928952 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b422d4860ecc85772f4ba8d9a195dd2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40d8b8621bff26d72e9625a367088e8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b67398a22c096cf620e030f99cd6b196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbadac5449c035770334f3d2b995092c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45933ba6d390b088cf6187774f097375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_109efc33839719ba0e15c31c9f21e2a0 |
| publicationDate | 2017-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2613071-C1 |
| titleOfInvention | N,n'-substituted 3,7-diazabicyclo[3.3.1]nonanes, pharmaceutical compositions based thereon and use thereof |
| abstract | FIELD: chemistry. n SUBSTANCE: present invention relates to N,N'-substituted 3,7-diazabicyclo[3.3.1]nonanes of general formula (1) 1, possessing properties of positive modulators of AMPA receptor activity, as well as to a pharmaceutical composition based thereon, use thereof in preventing and treating diseases of nervous system, in particular, neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, loss of memory, etc. In general formula (1) E is a carbonyl group, -CH 2 -group; R 1 is lower alkyl; R 2 together is selected from groups corresponding to general formulae (1.1a), (1.2a): (1.1a), (1.2a), R 8 is H, lower alkyl; R 5 , R 5 ', R 6 , R 6 ', R 7 and R 7 ' can be identical or different and each independently denotes H, lower alkyl; R 3 and R 3 ', R 4 and R 4 ' denote H. n EFFECT: prevention and treatment of diseases of nervous system, particularly neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, loss of memory, etc. n 11 cl, 8 tbl, 18 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2668982-C1 |
| priorityDate | 2015-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 210.